Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies.
Because of the need for control of beta-lactamase-mediated resistance and the recent development of tazobactam, the author has examined the inhibitors of various beta-lactamases for their effectiveness. On the basis of the kinetic data, tazobactam exhibited the highest affinity to various beta-lactamases. A combination with tazobactam was found to enhance the effectiveness of piperacillin against S. aureus producing penicillinase, E. coli producing TEM-1 or TEM 2 enzymes and class I beta-lactamase-derepressed isolates of E. cloacae, Serratia spp. and C. freundii, however not P. aeruginosa, while there was no marked synergism in beta-lactamase-derepressed clones of K. oxytoca.[1]References
- Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies. Cullmann, W. Zentralbl. Bakteriol. (1991) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg